Thus, it has been shown that using the CKD-EPI cystatin C-based eGFR (in contrast to the CAPA formula employed here), especially to predict disease progression and mortality in patients with mild CKD, offers no benefits and only increases costs [26]. This evidence concerns the gene CST3 and chronic kidney disease.